Narayana Hrudayalaya Ltd. — PPTs, 22-05-2026: Investor Presentation

**Business Performance:** Narayana Hrudayalaya delivered strong financial results for Q4 FY26, with consolidated operating revenues soaring 75.8% YoY to ₹2,593.8 Cr. Full-year FY26 revenues reached ₹7,896.0 Cr, up 44.0% YoY. EBITDA hit ₹539.2 Cr (20.8% margin) in Q4 FY26 and ₹1,716.9 Cr (21.7% margin) for FY26. PAT stood at ₹228.0 Cr (8.8% margin) for Q4 FY26 and ₹810.5 Cr (10.3% margin) for FY26, showcasing robust growth across operations.

**Growth Drivers & Strategy:** The company is aggressively expanding its footprint, targeting an additional 7,600+ beds by FY30 with significant greenfield and lease projects underway in Bangalore, Kolkata, and Raipur, involving substantial capex (e.g., ₹490 Cr for HSR, ₹900 Cr for Rajarhat). Digital transformation is a key focus, enhancing patient experience with apps, video consultations, and digitized consent, alongside expanding ATHMA Lab into new markets like UAE.

**Recent Developments:** Clinically, the group performed 750+ robotic cardiac surgeries in FY26 and opened new radiation therapy services in Mysuru and Iodine Therapy in Howrah. The UK operations, acquired in November 2025, are now contributing to the top line.

**Key Financial Metrics:** India hospital Average Revenue Per Occupied Bed (ARPOB) for Q4 FY26 was ₹1.86 Cr, up from ₹1.69 Cr YoY. The company maintains a healthy net debt-to-equity ratio of 0.49.

**Management Commentary / Outlook:** The company is committed to its "Health For All" ESG vision, setting ambitious targets for workforce training, patient care access, digital safety, and environmental sustainability, aiming for carbon neutrality by 2040.